To the UN, WHO, EU, Council of Europe and governments of all nations. Not to offend, damage or destroy, but to reflect, rebuild, inform and educate.
Surgical Oncologist IVAN KULIK not only derived a formula anticancer medicine, but was able to make it.
Author of FLARAXIN – IVAN KULIK was a Head of "HERBAL MEDICINE GROUP OF MALIGNANT TUMOURS" and a number of related research laboratories in the experiment proved that the New Anti-cancer medicine, herbal interferogen FLARAXIN has specificity for tumor processes, general pharmacological activity and safety.
It is irrefutable, legally documented that since 2010 it was the No Cancer Foundation who officially presented immunotherapy countless times to the various authorities with the request for studying immunomodulatory properties of FLARAXIN. However their answer was terror, collusion against No Cancer Foundation and partners. Please kindly read and forward this information as widely as possible so that we may shed the light of truth into the dark deceptions of pharmaceutical industrialists controlling medical and "public health" undermining the legitimacy, integrity, and credibility of health science.
Surgical Oncologist IVAN KULIK I.A. started research work on immunotherapy, studying immunomodulatory properties of FLARAXIN since 1979. On 8th July 1983, he filed an APPLICATION #3641428 in ROS-PATENT, and On 15th July 1994 performed registration in FEDERAL SERVICE FOR INTELLECTUAL PROPERTY
Cancer Curing Center PHOENIX LLC founded in 1996 to coordinate research work on a comprehensive study of a new anticancer medicine of plant origin FLARAXIN, which was developed in INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY of NATIONAL ACADEMY of SCIENCE of UKRAINE (NASU) by the surgical oncologist IVAN KULIK.
CCC Phoenix LLC developed and clinically tested a number of biologically active preparations of plant origin. For the first time, has been used a unique technology of plant concentrates, allowing several times to increase the biological activity of herbal extracts.
Now medications of CCC Phoenix LLC are used, as in oncology clinics, and medical centers of Ukraine and Russia.
INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY of NASU on June 9th 1990, it was reported in the Pharmacological Committee of the Ministry of Health of Ukraine that is a group of researchers of the Institute have developed a NEW ANTICANCER AGENT FLARAXIN.
INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY of NASU. Foundation of the Institute is fundamental research aimed at studying the pathogenetic mechanisms of formation of pathological conditions, general and specific features of physiologically active substances at different levels of organization of living matter - molecular, cellular, tissue, as well as in organs and body in general. One of the directions of the Institute - participation in the development and examination of state scientific and technical programs to create medicines, regulations and laws relating to the development and production of drugs. The Institute, a regulatory framework for regulation procedures pre-clinical study, examination and registration of medicines in Ukraine, methodological papers on pre-clinical study of medication. Director of the institute is Sc.D., Professor Tatiana A. BUHTIAROVA. Head of Department of Biochemical Pharmacology, corresponding member of NASU, Honored Worker of Science and Technology, Sc.D., professor - Y.I. GUBSKIY. Institute address: Ukraine, 03057, Kiev, Ezhena Potier st., 14.
INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY of NASU at the request of the MINISTRY OF HEALTH OF UKRAINE (MOZU) has developed TEMPORARY PHARMACEUTICAL ARTICLE (TPhA), and LABORATORY REGULATIONS FOR THE PRODUCTION OF FLARAXIN.
Surgical Oncologist IVAN KULIK I.A. started research work on FLARAXIN since 1979. On 8th July 1983, he filed an APPLICATION#3641428 in ROS-PATENT, and On 15th July 1994 performed registration in FEDERAL SERVICE FOR INTELLECTUAL PROPERTY (Rospatent) issued PATENT#2014082 for the INVENTION “ANTITUMOR AGENT-FLARAXIN”. After the collapse of the USSR, FLARAXIN was patented in Ukraine, under Patent #25833 dated 26th February 1999, the Bulletin number 1, as “The antitumor agent treatment of melanoblastoma”.
On the meeting of PE "STATE EXPERT CENTER" of MOZU. On 12th November 1990 adopted a resolution (Protocol#8) on FIRST PHASE I OF CLINICAL TRIALS (Production procedure of FLARAXIN and Instruction on FLARAXIN and Clinical Trials on patients with malignant melanoma).
Following the presentation of research centers of positive clinical trial results to the Ministry of Health of Ukraine at a meeting of PE "STATE EXPERT CENTER" of MOZU On 28 May, 1992, ALL RESULTS were APPROVED on the FIRST PHASE I OF CLINICAL TRIAL of the research and take a DECISION (Protocol#3) on SECOND PHASE II CLINICAL TRIALS that were also APPROVED for anti-melanoma medicine FLARAXIN.
Simultaneously, SCIENTIFIC RESEARCH INSTITUTE OF ONCOLOGY AND RADIOLOGY of MOZU (NATIONAL CANCER INSTITUTE (NCI) Chief oncologist MOZU, the Director of the National Cancer Institute, Sc.D., Professor Igor B. SCHEPOTIN.
The study find out that FLARAXIN have a high positive effect on the different indexes of various functioning parts of the immune system in cancer patients. This suggests that the known systemic immune deficiency caused by neoplastic process is subjected to positive correction due to the action of FLARAXIN.
The rehabilitation of functioning leading mechanisms of immune process by FLARAXIN is accompanied by improvements in overall clinical condition of the patients, resulting in a significant reduction or complete elimination of the metastatic process, the reduction and complete regression of tumor nodules.
Currently CCC PHOENIX LLC are working with (Protocol#8) that were appointed by PE "STATE EXPERT CENTER". of MOZU On 30th October 1997, and APPROVED by the President of PE "STATE EXPERT CENTER"of MOZU On 20th April, 1998. RESOLUTION OF THE STATE PHARMACOLOGICAL CENTER ON PRODUCTION OF FLARAXIN, signed by Director of MOZU, MD, Prof. - Alexander V. Stefanov, Doctor of Biological Sciences (1988), Professor (1996), Academician of the Academy of Medical Sciences of Ukraine (2002), laureate of the State Prize of Ukraine (2003), Director of the Institute of Pharmacology and Toxicology of the Academy of Medical Sciences of Ukraine (1992-2007); headed the State Enterprise "State Pharmacological Center of the Ministry of Health of Ukraine" (2000-2005). He made a great contribution to the organization of the LP examination system and the creation of a regulatory framework for the process of their registration in Ukraine and its harmonization with the requirements of world practice. Tel: +38 (044) 446-42-56, (044) 241-88-83. Address of MOZU: 01601-Kyiv, Grushevskogo st.,7, tel. +38 (044) 253-61-94, fax +38 (044) 253-40-17.
Doctors and employees of CCC PHOENIX LLC in collaboration with local scientists have developed a unique method of treatment of cancer patients, based on the use of mixed herbal extracts, which allows for an active influence on the cancer process at any stage of its development, in a variety of clinical forms.
High efficacy of preparations of CCC PHOENIX LLC with combination of their non- toxicity allows to use them in cases where other methods are contraindicated.
Licenses, patents and awards
All information posted on this web site is the opinion of the author and is provided for juridical and educational purposes only. It is not to be construed as medical advice. Only a licensed medical doctor can legally offer medical advice. Consult the healer of your choice for medical care and advice.